Follow-up of the prevention-of-NEC study by Oncel et al. 2014 with evaluation of neurological, neurosensory and cognitive status at 18-24 months’ corrected age in premature infants given L. reuteri DSM 17938 during their stay as newborn at the neonatal intensive care unit. Four hundred (400) completed the trial, 370 were eligible for follow-up and 249 (62%) were evaluated, whereof 124 received L. reuteri and 125 the placebo.
There was no significant difference in any of the neurodevelopmental and sensory outcomes between the two groups. Height and weight at time were not reported.
Conclusion: Oral administration of L. reuteri DSM 17938 to very low birth weight infants to reduce the incidence and severity of NEC, started with the first feed, did not affect neuromotor, neurosensory, and cognitive outcomes at 18-24 months’ corrected age.